Tempus AI
Tempus AI is a publicly traded precision medicine platform that combines genomic sequencing, multimodal clinical data, and AI to support oncology diagnosis and drug development. It operates exclusively in enterprise B2B channels — healthcare systems, pharma companies, and research institutions — with no SMB or self-serve pricing.
Multiple FDA-cleared AI products (ECG-MR, ECG-PH), Nature Medicine publication validating PRISM2 model, and AI-abstracted 60,000 patient records confirm strong core utility, but enterprise-only pricing with no self-serve access limits ROI accessibility severely, and no G2 product reviews were found to confirm user-level workflow impact.
No explicit public privacy policy details, GDPR status, or opt-out from AI training confirmed in evidence; genomic data aggregation at scale raises inherent privacy concerns; no SOC 2 or security certifications found; however, FDA regulatory oversight and institutional deployment provide some baseline trust floor.
Tempus is a publicly traded company (NASDAQ: TEM) with $9B market cap, $1B revenue, $3.06B total funding including Google and NEA, active pharma data licensing exceeding $1.1B TCV, and multiple recent high-profile regulatory clearances and ARPA-H selection, indicating strong market position and institutional adoption.
No public GitHub, no documented public SDK, and developer tooling appears entirely enterprise-gated; while internal infrastructure (Edge, Locker, Air, Model Inference API) is referenced, there is no publicly accessible API documentation, rate limits, or developer-facing resources confirming maturity for external integration.
Tempus AI is doing something genuinely difficult: turning the chaos of cancer patient data — genomics, imaging, pathology, clinical notes — into actionable intelligence at the point of care and the drug discovery lab bench. Since going public on Nasdaq in June 2024, it has grown revenue by 75–85% year over year, inked nine-figure deals with AstraZeneca and Gilead, and launched a steady drumbeat of new clinical products. The question isn't whether Tempus is building something important — it clearly is. The question is whether your organization is positioned to extract value from it.
Frequently asked
What is Tempus AI?
Tempus AI is a publicly traded precision medicine platform that combines genomic sequencing, multimodal clinical data, and AI to support oncology diagnosis and drug development. It operates exclusively in enterprise B2B channels — healthcare systems, pharma companies, and research institutions — with no SMB or self-serve pricing.
How much does Tempus AI cost?
Tempus AI uses a enterprise pricing model. See the pricing breakdown above for current plans.
What is Tempus AI best for?
Tempus AI is best suited for healthcare.
What is Tempus AI's StackScore?
Tempus AI scores 65/100 on Instawhat.ai's independent StackScore™ — a solid, competitive option.